<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">LUP</journal-id>
<journal-id journal-id-type="hwp">splup</journal-id>
<journal-id journal-id-type="nlm-ta">Lupus</journal-id>
<journal-title>Lupus</journal-title>
<issn pub-type="ppub">0961-2033</issn>
<issn pub-type="epub">1477-0962</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0961203312443992</article-id>
<article-id pub-id-type="publisher-id">10.1177_0961203312443992</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Concise reports</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Decreased breast cancer risk in systemic lupus erythematosus: the search for a genetic basis continues</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Bernatsky</surname><given-names>S</given-names></name>
<xref ref-type="aff" rid="aff1-0961203312443992">1</xref>
<xref ref-type="aff" rid="aff2-0961203312443992">2</xref>
<xref ref-type="corresp" rid="corresp1-0961203312443992"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Easton</surname><given-names>DF</given-names></name>
<xref ref-type="aff" rid="aff3-0961203312443992">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Dunning</surname><given-names>A</given-names></name>
<xref ref-type="aff" rid="aff3-0961203312443992">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Michailidou</surname><given-names>K</given-names></name>
<xref ref-type="aff" rid="aff3-0961203312443992">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Ramsey-Goldman</surname><given-names>R</given-names></name>
<xref ref-type="aff" rid="aff4-0961203312443992">4</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Gordon</surname><given-names>C</given-names></name>
<xref ref-type="aff" rid="aff5-0961203312443992">5</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Clarke</surname><given-names>AE</given-names></name>
<xref ref-type="aff" rid="aff1-0961203312443992">1</xref>
<xref ref-type="aff" rid="aff6-0961203312443992">6</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Foulkes</surname><given-names>W</given-names></name>
<xref ref-type="aff" rid="aff7-0961203312443992">7</xref>
</contrib>
</contrib-group>
<aff id="aff1-0961203312443992"><label>1</label>Division of Clinical Epidemiology, McGill University Health Centre, Montreal, Quebec, Canada</aff>
<aff id="aff2-0961203312443992"><label>2</label>Division of Rheumatology, McGill University Health Centre, Montreal, Quebec, Canada</aff>
<aff id="aff3-0961203312443992"><label>3</label>Department of Oncology/Public Health and Primary Care, University of Cambridge, Centre for Cancer Genetic Epidemiology, Strangeways Research Laboratory, Cambridge, UK</aff>
<aff id="aff4-0961203312443992"><label>4</label>Division of Rheumatology, Northwestern University, Chicago, USA</aff>
<aff id="aff5-0961203312443992"><label>5</label>Department of Rheumatology, Sandwell and West Birmingham Hospitals NHS Trust, City Hospital, Birmingham, UK</aff>
<aff id="aff6-0961203312443992"><label>6</label>Division of Allergy and Clinical Immunology, McGill University Health Centre, Montreal, Quebec, Canada</aff>
<aff id="aff7-0961203312443992"><label>7</label>Program in Cancer Genetics, Departments of Oncology and Human Genetics, McGill University, Montreal, Quebec, Canada</aff>
<author-notes>
<corresp id="corresp1-0961203312443992">Sasha Bernatsky, Division of Clinical Epidemiology, Research Institute of the McGill University Health Centre, 687 Pine Avenue West, V-Building, Room V2.09, Montreal, QuebecH3A 1A1, Canada Email: <email>sasha.bernatsky@mail.mcgill.ca</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>7</month>
<year>2012</year>
</pub-date>
<volume>21</volume>
<issue>8</issue>
<fpage>896</fpage>
<lpage>899</lpage>
<history>
<date date-type="received"><day>21</day><month>11</month><year>2011</year></date>
<date date-type="accepted"><day>24</day><month>2</month><year>2012</year></date>
</history>
<permissions>
<copyright-statement>© The Author(s), 2012. Reprints and permissions: http://www.sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p><bold>Purpose:</bold> Recent work has demonstrated an important decrease in breast cancers for women with systemic lupus erythematosus (SLE). The reason behind this phenomenon is unknown. Our purpose was to explore whether the single nucleotide polymorphisms (SNPs) predisposing to SLE might be protective against breast cancer (in women in the general population). <bold>Methods:</bold> We focused on loci relevant to 10 SNPs associated with SLE (with a <italic>p</italic> value of &lt;10<sup>−9</sup>). We determined whether we could establish a decreased frequency of these SNPs in breast cancer cases versus controls, within the general population. To do this we used a large breast cancer genome-wide association study (GWAS) dataset, involving 3,659 breast cancer cases and 4,897controls. These subjects were all primarily of European ancestry. <bold>Results:</bold> The population-based GWAS breast cancer data we examined suggested little evidence for important associations between breast cancer and SLE-related SNPs. Within the general population GWAS data, a cytosine(C) nucleotide substitution at rs9888739 (on chromosome 16p11.2) showed a very weak inverse association with breast cancer. The odds ratio (OR) for the rs9888739-C allele was 0.907551 (<italic>p</italic> value 0.049899) in the GWAS breast cancer sample, compared to controls. There was a slightly stronger, positive, association with breast cancer for rs6445975-G (Guanine) on chromosome 3p14.3, with a breast cancer OR of 1.0911 (<italic>p</italic> value 0.0097). <bold>Conclusions:</bold> Within this large breast cancer dataset, we did not demonstrate important associations with 10 lupus-associated SNPs. If decreased breast cancer risk in SLE is influenced by genetic profiles, this may be due to complex interactions and/or epigenetic factors.</p>
</abstract>
<kwd-group>
<kwd>Systemic lupus</kwd>
<kwd>breast cancer risk</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-0961203312443992" sec-type="intro"><title>Introduction</title>
<p>Systemic lupus erythematosus (SLE) is a prototypic autoimmune rheumatic disease affecting primarily women. Its prevalence increases with age; SLE and related systemic autoimmune rheumatic diseases affect about 1 in 100 women aged 65 and older,<sup><xref ref-type="bibr" rid="bibr1-0961203312443992">1</xref></sup> an age group at which breast cancer also becomes more prevalent. In our previous multi-centre cohort of cancer risk in SLE, breast cancers were one of the most common cancers, and accounted for about 10% of all cancers.<sup><xref ref-type="bibr" rid="bibr2-0961203312443992">2</xref></sup> However, when the risk of breast cancer in SLE is compared to breast cancer risk in an age-matched general population, it is apparent that there was actually an important decrease in breast cancers in women with SLE (<xref ref-type="table" rid="table1-0961203312443992">Table 1</xref>); the pooled standardized incidence ratio (SIR, ratio of observed to expected events) for breast cancer in SLE, across these studies, is 0.76 (95% confidence interval (CI): 0.69, 0.85).<sup><xref ref-type="bibr" rid="bibr3-0961203312443992">3</xref></sup> The reason behind this phenomenon is unknown. Our purpose was to explore whether certain single nucleotide polymorphisms (SNPs) of importance in SLE, might be protective against breast cancer (in women in the general population).
<table-wrap id="table1-0961203312443992" position="float"><label>Table 1</label><caption><p>Five recent large cohort studies in systemic lupus erythematosus: over-all, and breast cancer standardized incidence ratios (SIRs)</p></caption>
<graphic alternate-form-of="table1-0961203312443992" xlink:href="10.1177_0961203312443992-table1.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Study (with reference number)</th>
<th>Population</th>
<th><italic>N</italic> total</th>
<th>% females</th>
<th>Mean person-years of follow-up</th>
<th>Over-all cancer SIR (95% CI)<sup><xref ref-type="table-fn" rid="table-fn1-0961203312443992">a</xref></sup></th>
<th>Breast cancer SIR (95% CI)<sup><xref ref-type="table-fn" rid="table-fn1-0961203312443992">a</xref></sup></th></tr></thead>
<tbody align="left">
<tr>
<td>Bernatsky 2005<sup><xref ref-type="bibr" rid="bibr2-0961203312443992">2</xref></sup></td>
<td>International clinical</td>
<td>9547</td>
<td>90.2</td>
<td>6.0</td>
<td>1.15 (1.05–1.27)</td>
<td>0.76 (0.60, 0.96)</td></tr>
<tr>
<td>Bjornadal 2002<sup><xref ref-type="bibr" rid="bibr4-0961203312443992">4</xref></sup></td>
<td>Sweden administrative</td>
<td>5715</td>
<td>73.5</td>
<td>8.8</td>
<td>1.25 (1.14–1.37)</td>
<td>0.72 (0.54, 0.94)</td></tr>
<tr>
<td>Kang<sup><xref ref-type="table-fn" rid="table-fn2-0961203312443992">b</xref></sup> 2010<sup><xref ref-type="bibr" rid="bibr5-0961203312443992">5</xref></sup></td>
<td>South Korea clinical</td>
<td>914</td>
<td><xref ref-type="table-fn" rid="table-fn2-0961203312443992">b</xref></td>
<td>6.3</td>
<td>1.45 (0.74–2.16)</td>
<td>0.00<sup><xref ref-type="table-fn" rid="table-fn3-0961203312443992">c</xref></sup> (0.00, 3.06)</td></tr>
<tr>
<td>Mellemkjer 1997<sup><xref ref-type="bibr" rid="bibr6-0961203312443992">6</xref></sup></td>
<td>Denmark administrative</td>
<td>1585</td>
<td>83.0</td>
<td>6.8</td>
<td>1.30 (1.06–1.58)</td>
<td>1.00 (0.55, 1.68)</td></tr>
<tr>
<td>Parikh-Patel 2008<sup><xref ref-type="bibr" rid="bibr7-0961203312443992">7</xref></sup></td>
<td>USA administrative</td>
<td>30478</td>
<td>89.0</td>
<td>5.2</td>
<td>1.14 (1.07–1.20)</td>
<td>0.76 (0.67, 0.86)</td></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0961203312443992"><label>a</label><p>SIR: standardized incidence ratio, ratio of observed to expected cancers; CI: confidence interval. Pooled SIR for breast is 0.76(0.69, 0.85).</p></fn>
<fn id="table-fn2-0961203312443992"><label>b</label><p>Cohort included women only.</p></fn>
<fn id="table-fn3-0961203312443992"><label>c</label><p>No invasive breast cancers observed.</p></fn></table-wrap-foot>
</table-wrap></p></sec>
<sec id="sec2-0961203312443992" sec-type="materials|methods"><title>Materials and Methods</title>
<p>Genome-wide association studies (GWASs) entail examination of all or most of the genes (the genome) of a sample population, to see how much the genes vary from individual to individual. These studies can compare the deoxyribonucleic acid (DNA) of two groups: people with a disease of interest (cases) and similar people without that disease (controls), to detect important differences in allele frequencies. An allele which is found at higher frequencies in the cases than the controls (‘risk allele’) thus may represent a genetic determinant (or a marker) for the disease in question.</p>
<p>To perform our study we used recent breast cancer GWAS data, based on 3,659 breast cancer cases with a family history of the disease (recruited through the United Kingdom, UK, Familial Breast Cancer Study and the Prospective Study of Outcomes in Sporadic versus Hereditary Breast Cancer Study. Controls (<italic>N </italic>= 4,897) were drawn from the UK 1958 Birth Cohort and the UK National Blood Service, genotyped as part of the Wellcome Trust Case Control Consortium. The subjects (who are primarily of European ancestry), genotyping methods and analysis of the GWAS data have been described previously.<sup><xref ref-type="bibr" rid="bibr8-0961203312443992">8</xref></sup></p>
<p>These datasets have been analyzed and the frequencies of SNPs within the genome of the breast cancer patients (compared to the general population) are documented in databases held at the Centre for Cancer Genetic Epidemiology in Cambridge, UK.</p>
<p>We undertook to assess, within these data, the relative frequency (among breast cancer cases and controls) of alleles which have already been identified as being most robustly associated with SLE risk. To do so, we searched the National Human Genome Research Institute’s Catalog of Published Genome-Wide Association Studies (<ext-link ext-link-type="uri" xlink:href="http://www.genome.gov">http://www.genome.gov</ext-link>).<sup><xref ref-type="bibr" rid="bibr9-0961203312443992">9</xref></sup> Studies are identified through weekly PubMed literature searches and daily compilations of news and media reports, and are cross-referenced with the Human Genome Epidemiology (HuGE) Navigator to ensure no studies are missed. From this list we identified any alleles whose association had been verified in SLE populations of European ancestry. We also searched reviews of recent genome-wide association scans in lupus.<sup><xref ref-type="bibr" rid="bibr10-0961203312443992">10</xref>,<xref ref-type="bibr" rid="bibr11-0961203312443992">11</xref></sup></p>
<p>Since the more lupus-related genetic factors one assesses, the greater the chance of finding an additional association with breast cancer by chance, we restricted our evaluation to loci relevant for 10 lupus-associated alleles whose association with SLE reached a <italic>p</italic> value of 10<sup>−9</sup> or less. These loci are known to be relevant for SLE patients of European descent.</p></sec>
<sec id="sec3-0961203312443992" sec-type="results"><title>Results</title>
<p><xref ref-type="table" rid="table2-0961203312443992">Table 2</xref> shows the breast cancer odds ratios (ORs) generated from the general population GWAS, based on the 10 loci for lupus-associated SNPs that met our criteria. Though a few weak associations were possibly apparent, none were significant at the level of a Bonferoni-corrected <italic>p</italic> value of 0.005. Within the general population GWAS data, a cytosine (C) nucleotide substitution at rs9888739 (on chromosome 16p11.2) was suggested as possibly protective for breast cancer. The rs9888739 locus corresponds to an intron (a segment of gene that does not function in coding for protein) related to Integrin alpha M (ITGAM), a protein subunit of macrophage-1 antigen (Mac-1, also known as complement receptor 3, CR3). ITGAM is also known as CR3A, or as a cluster of differentiation molecule 11B (CD11B). It is involved in various adhesive properties of monocytes, macrophages and granulocytes and also in the phagocytosis of complement-coated particles.<sup><xref ref-type="bibr" rid="bibr12-0961203312443992">12</xref></sup> As is seen in the table, the OR for the rs9888739-C allele was 0.907551(<italic>p</italic> value 0.049899) in the GWAS breast cancer sample, compared to controls. However, the published association with SLE and the rs9888739 locus is with a thymine (T) nucleotide substitution.
<table-wrap id="table2-0961203312443992" position="float"><label>Table 2</label><caption><p>Breast cancer odds ratios (ORs) generated from General Population Genome Wide Association Studies (for 10 lupus-associated SNPs found in European populations)</p></caption>
<graphic alternate-form-of="table2-0961203312443992" xlink:href="10.1177_0961203312443992-table2.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Chromosome</th>
<th>SNP</th>
<th>Breast cancer OR</th>
<th>Breast cancer <italic>P</italic> value<sup><xref ref-type="table-fn" rid="table-fn4-0961203312443992">a</xref></sup></th>
<th>Locus</th></tr></thead>
<tbody align="left">
<tr>
<td>2q32.3</td>
<td>rs7574865</td>
<td>0.9948</td>
<td>0.8917</td>
<td>Signal transducer and activator of transcription 4, STAT4(intron)</td></tr>
<tr>
<td>3p14.3</td>
<td>rs6445975</td>
<td>1.0911</td>
<td>0.0097</td>
<td>Phosphoinositide-dependent kinase-1, PXK (intron)</td></tr>
<tr>
<td>4q24</td>
<td>rs10516487</td>
<td>0.9938</td>
<td>0.8516</td>
<td>B-cell scaffold protein with ankyrin repeats, BANK1 (missense)</td></tr>
<tr>
<td>5q33.3</td>
<td>rs2431697</td>
<td>1.0095</td>
<td>0.7618</td>
<td>Pituitary tumor transforming gene (PTTG)1 - ATP1(0B) (intergenic)</td></tr>
<tr>
<td>6p21.32</td>
<td>rs2187668</td>
<td>1.0003</td>
<td>0.9948</td>
<td>Human Leukocyte Antigen, HLA-DR3, HLA-DQA1 (intron)</td></tr>
<tr>
<td>6p21.32</td>
<td>rs3129860</td>
<td>1.0302</td>
<td>0.4993</td>
<td>HLA-DR2 (telomeric)</td></tr>
<tr>
<td>6q23.3</td>
<td>rs5029937</td>
<td>1.0596</td>
<td>0.5037</td>
<td>Tumor necrosis factor (TNF) AI (intron)</td></tr>
<tr>
<td>7q32.1</td>
<td>rs10488631</td>
<td>1.0458</td>
<td>0.3683</td>
<td>Interferon regulatory factor 5(IRF5)- TNPO3 (intergenic)</td></tr>
<tr>
<td>8p23.1</td>
<td>rs13277113</td>
<td>1.0353</td>
<td>0.3368</td>
<td>C8orf13, B lymphoid tyrosine kinase (BLK), FAM167A – BLK (intergenic)</td></tr>
<tr>
<td>16p11.2</td>
<td>rs9888739</td>
<td>0.9076</td>
<td>0.0499</td>
<td>ITGAM (intron)</td></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn4-0961203312443992"><label>a</label><p>The Bonferoni-corrected <italic>p</italic> value for significance is 0.005. SNP: single nucleotide polymorphism.</p></fn></table-wrap-foot>
</table-wrap></p>
<p>There was a slightly stronger, and positive, association with breast cancer at rs6445975 (on chromosome 3p14.3) with an OR of 1.0911 (<italic>p</italic> value 0.0097) within the GWAS breast cancer cases versus controls. This locus corresponds to an intron related to3'-phosphoinositide-dependent kinase-1 (PDK-1), a serine/threonine protein kinase which is an important modulator of cancer cell growth.<sup><xref ref-type="bibr" rid="bibr13-0961203312443992">13</xref></sup> In the breast cancer subjects examined, the risk allele most commonly featured rs6445975-G (Guanine) while rs6445975-T is protective for breast cancer. In contrast, in SLE patients, lupus risk is associated with rs6445975-C.</p></sec>
<sec id="sec4-0961203312443992" sec-type="discussion"><title>Discussion</title>
<p>SLE is a complex genetic disease; single gene defects (e.g. homozygous deficiency of components in the classic complement pathways) are the cause of SLE in only a tiny proportion of patients.<sup><xref ref-type="bibr" rid="bibr14-0961203312443992">14</xref></sup> Instead, for the vast majority of patients, variation at multiple genetic loci contributes to risk. Early studies of candidate genes and linkage approaches identified lupus-related variation in several loci, including the human leukocyte antigen (HLA) region, signal transducer and activator of transcription 4 (STAT4), interferon regulatory factor 5 (IRF5), and others. GWA studies have confirmed and expanded the list of SLE risk loci to over 25, including the 10 featured here.<sup><xref ref-type="bibr" rid="bibr15-0961203312443992">15</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr19-0961203312443992">19</xref></sup></p>
<p>Since SLE itself is a complex genetic disease, it is unlikely that a single genetic factor would drive the decreased breast cancer risk in SLE. At the same time, an individual’s genetic predisposition to breast cancer is the sum of all the genetic variability that occurs at the level of various SNPs throughout the genome, which is in turn influenced by the recombination events at the time of conception. Based on breast cancer GWAS data in the general population, loci associated with breast cancer have been confirmed for a diverse number of chromosomes, including 1p11.2, 2q35, 3p, 5p12, 8q24, 10q23.13, 14q24.1 and 16q. These genes are linked with important functions in pathways as diverse as regulation of the cytoskeleton, drug metabolism, and circadian rhythms.<sup><xref ref-type="bibr" rid="bibr20-0961203312443992">20</xref></sup></p>
<p>We did not specifically choose alleles for study on the basis of those most likely to have a biological effect on breast cancer, since the potential biological relationship between SLE and breast cancer is so poorly elucidated. It is theoretically possible that one of the many pathways that allow the immune system to be excessively active in SLE, could decrease breast cancer risk through augmented immunosurveillance. Alternatively, drug exposures in SLE (such as anti-malarial agents or non-steroidal anti-inflammatories) theoretically could mediate some of the decreased breast cancer risk, but our preliminary case-control analyses in SLE subjects have to date shown little evidence that protection against breast cancer risk in SLE, is due to lupus treatment.</p>
<p>The strength of our evaluation was that we assessed loci related to ten lupus-associated SNPs in a very large population of women with breast cancer and controls. Despite the large dataset, we remain unable to explain, on the basis of the genetic factors studied, why women with SLE have such a pronounced decreased breast cancer risk. Thus, if genetic factors do drive this phenomenon, it is likely due to either combinations of genetic factors (e.g. multiple lupus-associated SNPs present in the same individuals), or to interactions between the environment and genetic factors. To explore this might require evaluation of the genetic profiles of breast cancer patients and controls (in terms of lupus-related SNPs) with stratification based on key factors such as menopausal status.</p>
<p>In summary, the population-based GWAS breast cancer data we examined suggested little evidence for relationships with these lupus-related SNPs known to be important in patients of European descent. If genetic factors do drive the decreased breast cancer risk in SLE, it must be due to more complex phenomena, such as combinations of SNPs, or gene–environment interactions. These hypotheses would need to be investigated further.</p>
<p>Potential future directions could also involve implementing the reverse approach in GWAS of SLE populations, to determine if SNPs known to be associated with breast cancer are in fact represented less often in SLE than in the general population.</p></sec>
</body>
<back>
<sec id="sec5-0961203312443992"><title>Funding</title>
<p>The following funding sources are acknowledged: Cancer Research UK (grant numbers A10119, A10123, A10118, A11021).</p></sec>
<sec id="sec6-0961203312443992"><title>Conflict of interest</title>
<p>The authors declare no conflict of interest.</p></sec>
<ref-list>
<title>References</title>
<ref id="bibr1-0961203312443992"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bernatsky</surname><given-names>S</given-names></name><name><surname>Lix</surname><given-names>L</given-names></name><name><surname>Hanly</surname><given-names>JG</given-names></name><etal/></person-group>. <article-title>Surveillance of systemic autoimmune rheumatic diseases using administrative data</article-title>. <source>Rheumatol Int</source> <year>2011</year>; <volume>31</volume>: <fpage>549</fpage>–<lpage>554</lpage>.</citation></ref>
<ref id="bibr2-0961203312443992"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bernatsky</surname><given-names>S</given-names></name><name><surname>Boivin</surname><given-names>J</given-names></name><name><surname>Lawrence</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>An international cohort study of cancer in systemic lupus erythematosus</article-title>. <source>Arthritis &amp; Rheumatism</source> <year>2005</year>; <volume>52</volume>: <fpage>1481</fpage>–<lpage>1490</lpage>.</citation></ref>
<ref id="bibr3-0961203312443992"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bernatsky</surname><given-names>S</given-names></name><name><surname>Ramsey-Goldman</surname><given-names>R</given-names></name><name><surname>Foulkes</surname><given-names>W</given-names></name><name><surname>Gordon</surname><given-names>C</given-names></name><name><surname>Clarke</surname><given-names>A</given-names></name></person-group>. <article-title>Breast, Ovarian, and endometrial malignancies in systemic lupus erythematosus: A meta-analysis</article-title>. <source>British Journal of Cancer</source> <year>2011</year>; <volume>104</volume>: <fpage>1478</fpage>–<lpage>1481</lpage>.</citation></ref>
<ref id="bibr4-0961203312443992"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Björnådal</surname><given-names>L</given-names></name><name><surname>Löfström</surname><given-names>B</given-names></name><name><surname>Yin</surname><given-names>L</given-names></name><name><surname>Lundberg</surname><given-names>IE</given-names></name><name><surname>Ekbom</surname><given-names>A</given-names></name></person-group>. <article-title>Increased cancer incidence in a Swedish cohort of patients with systemic lupus erythematosus</article-title>. <source>Scand J Rheumatol</source> <year>2002</year>; <volume>31</volume>(<issue>2</issue>): <fpage>66</fpage>–<lpage>71</lpage>.</citation></ref>
<ref id="bibr5-0961203312443992"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>KY</given-names></name><name><surname>Kim</surname><given-names>HO</given-names></name><name><surname>Yoon</surname><given-names>HS</given-names></name><etal/></person-group>. <article-title>Incidence of cancer among female patients with systemic lupus erythematosus in Korea</article-title>. <source>Clin Rheumatol</source> <year>2010</year>; <volume>29</volume>: <fpage>381</fpage>–<lpage>388</lpage>.</citation></ref>
<ref id="bibr6-0961203312443992"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mellemkjaer</surname><given-names>L</given-names></name><name><surname>Andersen</surname><given-names>V</given-names></name><name><surname>Linet</surname><given-names>MS</given-names></name><name><surname>Gridley</surname><given-names>G</given-names></name><name><surname>Hoover</surname><given-names>R</given-names></name><name><surname>Olsen</surname><given-names>JH</given-names></name></person-group>. <article-title>Non-Hodgkin's lymphoma and other cancers among a cohort of patients with systemic lupus erythematosus</article-title>. <source>Arthritis Rheum</source> <year>1997</year>; <volume>40</volume>: <fpage>761</fpage>–<lpage>768</lpage>.</citation></ref>
<ref id="bibr7-0961203312443992"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Parikh-Patel</surname><given-names>A</given-names></name><name><surname>White</surname><given-names>RH</given-names></name><name><surname>Allen</surname><given-names>M</given-names></name><name><surname>Cress</surname><given-names>R</given-names></name></person-group>. <article-title>Cancer risk in a cohort of patients with systemic lupus erythematosus (SLE) in California</article-title>. <source>Cancer Causes Control</source> <year>2008</year>; <volume>Oct;19</volume>(<issue>8</issue>): <fpage>887</fpage>–<lpage>894</lpage>. <comment>Epub 2008 Apr 2. PubMed PMID: 18386139</comment>.</citation></ref>
<ref id="bibr8-0961203312443992"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Turnbull</surname><given-names>C</given-names></name><name><surname>Ahmed</surname><given-names>S</given-names></name><name><surname>Morrison</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Genome-wide association study identifies five new breast cancer susceptibility loci</article-title>. <source>Nat Genet</source> <year>2010</year>; <volume>42</volume>: <fpage>504</fpage>–<lpage>507</lpage>.</citation></ref>
<ref id="bibr9-0961203312443992"><label>9</label><citation citation-type="other"><comment>Hindorff LA, Junkins HA, Hall PN, Mehta JP, Manolio TA. A Catalog of Published Genome-Wide Association Studies. <ext-link ext-link-type="uri" xlink:href="http://www.genome.gov/gwastudies/">http://www.genome.gov/gwastudies/</ext-link> (2011, accessed 24 March 2012)</comment>.</citation></ref>
<ref id="bibr10-0961203312443992"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>H</given-names></name><name><surname>Feng</surname><given-names>JB</given-names></name><name><surname>Pan</surname><given-names>HF</given-names></name><etal/></person-group>. <article-title>A meta-analysis of the association of STAT4 polymorphism with systemic lupus erythematosus</article-title>. <source>Mod Rheumatol</source> <year>2010</year>; <volume>20</volume>: <fpage>257</fpage>–<lpage>262</lpage>.</citation></ref>
<ref id="bibr11-0961203312443992"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Graham</surname><given-names>RR</given-names></name><name><surname>Hom</surname><given-names>G</given-names></name><name><surname>Ortmann</surname><given-names>W</given-names></name><name><surname>Behrens</surname><given-names>TW</given-names></name></person-group>. <article-title>Review of recent genome-wide association scans in lupus</article-title>. <source>J Intern Med</source> <year>2009</year>; <volume>265</volume>: <fpage>680</fpage>–<lpage>688</lpage>.</citation></ref>
<ref id="bibr12-0961203312443992"><label>12</label><citation citation-type="other"><comment>Genes-to-Systems Breast Cancer Database. <ext-link ext-link-type="uri" xlink:href="http://www.itb.cnr.it/breastcancer/">http://www.itb.cnr.it/breastcancer/</ext-link> (2011, accessed 24 March 2012)</comment>.</citation></ref>
<ref id="bibr13-0961203312443992"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Raimondi</surname><given-names>C</given-names></name><name><surname>Falasca</surname><given-names>M</given-names></name></person-group>. <article-title>Targeting PDK1 in cancer</article-title>. <source>Curr Med Chem</source> <year>2011</year>; <volume>18</volume>: <fpage>2763</fpage>–<lpage>2769</lpage>.</citation></ref>
<ref id="bibr14-0961203312443992"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Harley</surname><given-names>JB</given-names></name><name><surname>Moser</surname><given-names>KL</given-names></name><name><surname>Gaffney</surname><given-names>PM</given-names></name><name><surname>Behrens</surname><given-names>TW</given-names></name></person-group>. <article-title>The genetics of human systemic lupus erythematosus</article-title>. <source>Curr Opin Immunol</source> <year>1998</year>; <volume>10</volume>: <fpage>690</fpage>–<lpage>696</lpage>.</citation></ref>
<ref id="bibr15-0961203312443992"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hom</surname><given-names>G</given-names></name><name><surname>Graham</surname><given-names>RR</given-names></name><name><surname>Modrek</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX</article-title>. <source>N Engl J Med</source> <year>2008</year>; <volume>358</volume>: <fpage>900</fpage>–<lpage>909</lpage>.</citation></ref>
<ref id="bibr16-0961203312443992"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kozyrev</surname><given-names>SV</given-names></name><name><surname>Abelson</surname><given-names>AK</given-names></name><name><surname>Wojcik</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Functional variants in the B-cell gene BANK1 are associated with systemic lupus erythematosus</article-title>. <source>Nat Genet</source> <year>2008</year>; <volume>40</volume>: <fpage>211</fpage>–<lpage>216</lpage>.</citation></ref>
<ref id="bibr17-0961203312443992"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nath</surname><given-names>SK</given-names></name><name><surname>Han</surname><given-names>S</given-names></name><name><surname>Kim-Howard</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>A nonsynonymous functional variant in integrin-alpha(M) (encoded by ITGAM) is associated with systemic lupus erythematosus</article-title>. <source>Nat Genet</source> <year>2008</year>; <volume>40</volume>: <fpage>152</fpage>–<lpage>154</lpage>.</citation></ref>
<ref id="bibr18-0961203312443992"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Remmers</surname><given-names>EF</given-names></name><name><surname>Plenge</surname><given-names>RM</given-names></name><name><surname>Lee</surname><given-names>AT</given-names></name><etal/></person-group>. <article-title>STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus</article-title>. <source>N Engl J Med</source> <year>2007</year>; <volume>357</volume>: <fpage>977</fpage>–<lpage>986</lpage>.</citation></ref>
<ref id="bibr19-0961203312443992"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sigurdsson</surname><given-names>S</given-names></name><name><surname>Nordmark</surname><given-names>G</given-names></name><name><surname>Goring</surname><given-names>HH</given-names></name><etal/></person-group>. <article-title>Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus</article-title>. <source>Am J Hum Genet</source> <year>2005</year>; <volume>76</volume>: <fpage>528</fpage>–<lpage>537</lpage>.</citation></ref>
<ref id="bibr20-0961203312443992"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Humphreys</surname><given-names>K</given-names></name><name><surname>Heikkinen</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>A combined analysis of genome-wide association studies in breast cancer</article-title>. <source>Breast Cancer Res Treat</source> <year>2011</year>; <volume>126</volume>: <fpage>717</fpage>–<lpage>727</lpage>.</citation></ref>
</ref-list>
</back>
</article>